LMU researchers have successfully tested a new drug which can significantly extend the lives of breast cancer patients.
AbbVie touts Skyrizi ulcerative colitis data as it eyes another indication
AbbVie has touted Skyrizi as a key pillar of its future beyond Humira, and on Thursday, the company read out results suggesting the IL-23 inhibitor